AI Drug Discovery for Pharma and Biotech

Drug discovery

803

papers

On emerging therapies

Overview

Squamous cell carcinoma (SCC) of the penis accounts for 95% of penile malignancies, primarily affecting older uncircumcised men with risk factors such as HPV infection, poor genital hygiene, and smoking. Early-stage disease is highly curable with penile-sparing surgeries (e.g., Mohs micrographic surgery, laser ablation), while advanced cases require multimodal approaches combining chemotherapy, radiation, and lymph node dissection. HPV-positive tumors may respond better to targeted therapies, though survival rates drop sharply with lymph node involvement or metastasis [1][2][9][14].

Population

  • Most common in men aged 50–70, with higher incidence in low-income regions (e.g., Brazil: 2.8–6.8/100,000 vs. 0.1/100,000 in Israel) [6][18].

  • Strongly associated with uncircumcision, HPV (16/18 subtypes), phimosis, and low socioeconomic status [2][6][14].

Burden

  • Age-adjusted incidence: 0.81/100,000 in the U.S., with 30-50% mortality in stage IV disease [4][6].

  • Disproportionately impacts Hispanic men (72% higher incidence) and Black populations (younger diagnosis age, worse survival) [4][6].

  • Quality-of-life challenges: 20-30% recurrence risk after organ-sparing surgery vs. 5% with penectomy [3][15].

Therapies

  • Localized disease: Penile preservation techniques (glans resurfacing, Mohs surgery) achieve 94.7% cure rates for carcinoma in situ [2][15].

  • Advanced/metastatic: Neoadjuvant TIP chemotherapy (taxane/ifosfamide/cisplatin) for node-positive cases, followed by inguinal lymphadenectomy [3][11].

  • Emerging options: Immune checkpoint inhibitors and HPV-directed therapies under investigation in clinical trials (e.g., InPACT trial) [3][19].

Categories: rare neoplastic diseases, rare urogenital diseases

Research Papers

803 drug discovery papers about Squamous cell carcinoma of the penis, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

803 drug discovery papers about Squamous cell carcinoma of the penis, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-09-08 | Epidemiological trends in penile cancer and the evolving role of dynamic sentinel lymph node biopsy.

Penile cancer (PeCa) is a rare but aggressive malignancy with growing global incidence. The most influential prognostic factor in PeCa is the presence of nodal metastasis. Current imaging modalities lack the diagnostic accuracy to reliably detect micro-metastasis in PeCa. Since 2015, Dynamic Sentinel Lymph Node Biopsy (DSLNBx) emerged as a means of accurately detecting nodal metastases in PeCa. The impact of DSLNBx on overall and cancer-specific survival years remains to be established in the Irish population. Population based data was obtained from The National Cancer Registry of Ireland (NCRI) on all patients diagnosed with PeCa between 1994 and 2021. Log-rank Mantel-Cox analysis was applied to assess survival benefit associated with DSLNBx. A total of 866 patients were diagnosed with PeCa in Ireland between 1994 and 2021 with population standardized incidence incrementing from 1.68 to 2.80 cases/100,000 males/year during this period. The most common histological subtype was squamous cell carcinoma (92.8%) followed by melanoma (2.7%), basal cell carcinoma (0.7%). Surgical excision constituted mainstay treatment (86.2%). DSLNBx was performed in 8% of cases of which 13% had node positive disease. Those who underwent DSLNBx were found to have a statistically significant increase in overall survival rate, χ2 (1) = 4.067, P = 0.044. Cancer specific survival rate correlated positively in those who underwent DSLNBx also, but this did not reach statistical significance. PeCa has growing incidence in Ireland. DSLNBx offers a means of accurately assessing presence of nodal metastasis whilst incurring minimal morbidity which has been associated with improved overall survival on univariate analysis.

Open article ↗



2026-09-07 | Apatinib monotherapy for pretreated advanced squamous cell carcinoma of the penis: a phase 2 trial.

Treatment options for patients with advanced penile squamous cell carcinoma who have disease progression on systemic chemotherapy are scarce. Antiangiogenic drugs have shown antitumor effects in case series. This phase 2 trial evaluated the activity and safety of apatinib (a Vascular Endothelial Growth Factor (VEGF) receptor inhibitor) in such patients. This investigator-initiated, single-arm, phase 2 trial was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN000021849) and performed at a tertiary cancer center in Shanghai, China. Eligible patients had histologically confirmed penile squamous cell carcinoma, were not candidates for surgery with curative intent, had measurable disease, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, pretreated with one or more kinds of systemic treatment. Patients were prescribed oral apatinib 500 mg daily with the option of dose reduction to manage adverse events. The primary endpoint was the investigator-assessed overall response rate (ORR) assessed in all patients who received at least one dose of study drug. Between 2016 and 2023, we enrolled 23 patients, all of whom received at least one dose of study treatment. Of the 23 patients, 16 had an ECOG performance status of 2. Only 6 patients had human papillomavirus-positive tumors. Five patients had a partial response (ORR = 22% [95% CI, 10%-42%]). The median progression-free survival was 3.8 months, and median overall survival was 7.2 months. Treatment-related adverse events of grade 3 or worse occurred in 7 (30%) of 23 patients. The most common grade 3 or 4 treatment-related adverse events were hand-foot syndrome (13%), hypertension (9%), and increase in serum alanine aminotransferase (9%). Apatinib in pretreated advanced penile cancer showed limited efficacy with a manageable safety profile. UMIN000021849.

Open article ↗



2026-08-26 | Assessment of EGFR and HER2 expression in penile cancer as potential therapeutic targets.

Penile cancer (PC) is a rare but aggressive malignancy with limited systemic treatment options, particularly in advanced stages. Targeted therapies against receptor tyrosine kinases such as EGFR and HER2 have demonstrated clinical benefit in other cancer types, yet their role in PC remains poorly defined. Understanding their expression patterns in primary tumors and metastases is essential for identifying new therapeutic avenues. In this study, we aimed to systematically assess the expression of EGFR and HER2 in a large multicenter PSCC cohort and evaluate their potential relevance not only as therapeutic targets but also as prognostic biomarkers. In addition, we analyzed possible correlations with key clinicopathological features, including HPV status, tumor stage and histological subtype. Among 208 patients, moderate to strong EGFR expression was detected in 27.0% of primary tumors and 29.0% of metastases, with HER2 overexpression observed in 7.0% and 21.4%, respectively. EGFR expression was significantly higher in HPV-negative tumors and associated with reduced overall survival. In contrast, HER2 was more frequently overexpressed in HPV-positive and basaloid tumors without prognostic significance. Expression patterns of both markers were largely homogeneous within primary tumors but showed partial discordance between primary and metastatic lesions. EGFR and HER2 are variably expressed in PC, with EGFR displaying potential as a prognostic marker. These findings suggest that both receptors may serve as therapeutic targets in certain patients, particularly if confirmed in metastases. Future research should integrate molecular profiling to refine biomarker-based stratification and guide the use of targeted therapies in this rare but challenging cancer.

Open article ↗



2026-08-24 | Randomized trial of adjuvant 5-FU-platinum vs paclitaxel-platinum for high-risk penile cancer.

Adjuvant chemotherapy is recommended for high-risk penile squamous cell carcinoma (SCC) metastatic to lymph nodes based on retrospective data, but no randomized trials have been conducted. We compared 5-fluorouracil (5-FU)-platinum with paclitaxel-platinum in this setting. In this open-label, randomized trial at an Indian tertiary cancer center, men <70 years with resected node-positive penile SCC and ≥1 high-risk feature (perinodal extension, pelvic node involvement, >1 inguinal nodes, or ≥ 4 cm node) were assigned 1:1 to four 3-weekly cycles of 5-FU-platinum or paclitaxel-platinum, followed by cisplatin-based chemoradiotherapy. Primary endpoint was disease-free survival (DFS). Secondary endpoints were overall survival (OS), toxicity, and quality-of-life (QoL). Between 2017 and 2024, 49 patients were randomized (5-FU-platinum: 25, paclitaxel-platinum: 24). At a median follow-up of 69 months, median DFS was 12.4 months (95% CI, 3.38-NR) vs 19.6 months (95% CI, 5.82-NR) (HR, 1.16; 95% CI, 0.55-2.45; P = 0.686) and median OS was 21.3 vs 36.7 months (HR, 1.13; 95% CI, 0.52-2.44; P = 0.754) for 5-FU-platinum and paclitaxel-platinum, respectively. Grade ≥3 toxicities occurred in 77.3% vs 40.9% (P = 0.014), grade ≥3 hematologic toxicities in 54.5% vs 4.5% (P < 0.001), and hospitalization for toxicity in 45.5% vs 9.1% (P = 0.016). Completion of all planned cycles was higher with paclitaxel-platinum (83.3% vs 48%; P = 0.009). QoL and sexual health were similar between the two treatment arms. Adjuvant paclitaxel-platinum was associated with improved tolerability compared with fluorouracil-platinum in high-risk node positive penile cancer and warrants further evaluation in larger multicenter studies. Early termination precluded definitive efficacy comparisons. Clinical Trials Registry of India (CTRI/2016/12/007567). This work was supported by Indian Cooperative Oncology Network and Tata Memorial Center.

Open article ↗



2026-08-07 | Intratumoral para-toluenesulfonamide as a tumor-ablative therapy for equine cutaneous tumors: a case series of three horses.

Equine neoplasia, including sarcoids, melanomas, and squamous cell carcinomas, presents therapeutic challenges due to recurrence and limitations of conventional treatments. Para-toluenesulfonamide (p-TLS) is a tumor-ablating agent that is associated with localized tumor necrosis and subsequent lesion resolution. It has been evaluated in human clinical settings as an intratumoral treatment of malignant airway obstruction caused by non-small cell lung cancer. This study aimed to describe the clinical outcomes and tolerability of intratumoral p-TLS in equine neoplasia. Three equine cases, including a fibroblastic sarcoid, perianal melanoma, and penile squamous cell carcinoma, were treated. The fibroblastic sarcoid and penile squamous cell carcinoma achieved complete response. The melanoma fulfilled the criteria for partial response at the protocol-defined clinical evaluation timepoint and subsequently demonstrated complete clinical resolution during follow-up. All cases demonstrated a consistent pattern of response characterized by tumor necrosis, sloughing, and subsequent wound healing with complete re-epithelialization. Local adverse effects were limited to transient inflammation and mild discomfort, which were effectively managed with supportive care. No severe adverse events or tumor recurrence were observed during the follow-up period ranging from 120 days to 15 months. These findings suggest that p-TLS may represent a feasible, highly minimally invasive intratumoral therapeutic approach for equine neoplasia and support further evaluation.

Open article ↗



cell therapies
2022-12-15 | Establishment and Characterization of Advanced Penile Cancer Patient-derived Tumor Xenografts: Paving the Way for Personalized Treatments.

Systemic treatments for penile squamous cell carcinoma (pSCC) are toxic and inefficient. Patient-based preclinical models are essential to study novel treatments. To establish a library of patient-derived tumor xenograft (PDX) models of human papillomavirus-positive (HPV+) and -negative (HPV-) pSCC and characterize these at the genomic and histological levels. Eighteen tumor samples from 14 patients with recurrent or metastatic pSCC were implanted in nude mice. A biobank of PDX tumors was established after passaging of patient samples (F0) for three generations (F1, F2, F3) and was characterized using histopathology and targeted next-generation sequencing (tNGS). Single-nucleotide polymorphism fingerprinting was used to confirm PDX genealogy. The engraftment rate, overall growth rate, and pSCC histomorphology were checked for each PDX generation. Staining for p40 (a pSCC marker) and p16 (a surrogate for HPV infection) was performed for F0 samples. The mutational profile according to a validated panel of 96 cancer genes was determined for F0 and F3 samples and compared to a larger tNGS database. Including a previously established pilot model, 11 out of 18 tumor samples (61%) successfully engrafted in F1. The mean time from implantation in F1 to completion of F3 was 36 wk (standard deviation 18). Histological fidelity was demonstrated across generations. The patient mutational profiles were preserved in F3 and were representative of 277 pSCC samples in the Foundation Medicine database. The rapid progression of pSCC in patients from our selected high-risk cohort impeded the use of PDXs as avatars. We successfully established the first library of 11 PDX models of HPV- and HPV+ pSCC. Our PDX models showed high engraftment rates and histological and genomic fidelity to the tumor tissue of origin. These models may help in paving the way towards the development of novel treatments. We established 11 animal models based on tumor tissue from patients with penile cancer. These models could play a vital role in selection of novel treatments according to genetic mutations. In the future, therapies with confirmed preclinical effects may have a profound impact on the development of personalized treatments in penile cancer.

Open article ↗



2021-06-09 | Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients.

Penile cancer is a rare but highly lethal cancer, and therapeutic options for patients presenting with lymph nodal disease are very limited. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) was shown to provide durable objective response in patients with metastatic melanoma and TIL have been expanded from solid tumors at rates between 70 and 90% depending on the specific diagnosis. We evaluated whether TIL could be expanded from surgical specimens of patients with penile cancer. Tumor samples from metastatic lymph nodes obtained at the time of inguinal lymph node dissection were collected, minced into fragments, placed in individual wells of a 24-well plate, and propagated in high dose IL-2 for four weeks. The phenotype of expanded TILs was assessed by flow cytometry and their anti-tumor reactivity was assessed by IFN-γ ELISA. TIL were expanded from 11 out of 12 (91.6%) samples of metastatic lymph nodes. Expanded TIL were predominantly CD3+ (mean 67.5%, SD 19.4%) with a mean of 46.8% CD8+ T cells (SD 21.1%). Five out of 11 samples (45.4%) from expanded TIL secreted IFN-γ in response to autologous tumor. TIL expansion and phenotype of expanded T cell lymphocytes were independent of previous HPV infection and treatment with neoadjuvant chemotherapy. This is the first report demonstrating successful expansion of tumor-reactive TIL from penile cancer patients, which support development of ACT strategies using TIL for the treatment of advanced and recurrent penile cancer.

Open article ↗



2019-09-01 | Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer

Treatment of locoregionally advanced penile squamous cell carcinoma (LAPSCC) is challenging. The exact role (in terms of oncological benefit) of extensive surgery is not well established. Moreover, surgery invariably leads to large defects requiring reconstructive surgery. Rectus abdominis myocutaneous (RAM) and abdominal advancement flaps have an independent and constant blood supply, are easily harvested, and provide substantial skin coverage and soft tissue.To determine the surgical and oncological outcomes in patients with LAPSCC undergoing surgical resection with RAM flaps.From 2002 to 2016, a multi-institutional database identified 15 LAPSCC patients undergoing flap reconstructions.Local surgical resection with RAM or abdominal advancement flap reconstruction.Perioperative and pathologic data were collected. Postoperative complications were identified using the Clavien-Dindo classification for surgical complications.Fifteen patients (median age 61 yr) were treated, ten with curative intent. Thirteen patients received induction chemotherapy. Thirteen of the 15 patients (87%) experienced wound complications, including five Clavien-Dindo grade III complications. In 11/15 patients (73%), the disease recurred (median recurrence-free interval 106 d). The majority of recurrences (91%) were locoregional, and in four cases the patient also had lesions in distant organs. Ten of the 15 patients (67%) died of their disease. The overall median follow-up interval was 10.5 mo. The study was limited by its retrospective design, the absence of quality-of-life measurements, and the cohort size.The results of this study show that surgical resection with reconstruction is associated with a risk of perioperative complications, including high-grade Clavien-Dindo complications. With a cure rate of 27%, surgery must be carefully considered and there is a need for alternative treatments. Lack of robust quality-of-life-data is also a serious shortcoming in the decision process for this patient category.Surgery in locoregionally advanced penile cancer has a low cure rate. Reconstruction of defects is surgically feasible, albeit with a high risk of complications. Furthermore, decision-making lacks robust data on quality of life after surgery.

Open article ↗



2018-06-07 | Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines

Abstract Cell line models are essential tools to study the molecular mechanisms underlying tumor initiation and progression. There are limited treatment options for penile squamous cell carcinoma (PSCC), accounting for 1–2% of male tumors in developing countries, and limited progress in preclinical research in PSCC due to lacking available models with identified genomic characteristics. Here, biological and molecular characteristics and whole-genomic alterations were analyzed in a panel of PSCC cell lines newly established in our laboratory. These cell lines were all human papillomavirus (HPV)-negative, epithelial-like, immortalized, and tumorigenic in nude mice, whereas they displayed different proliferation, migration and invasion capacities in vitro, and tumorigenic ability in nude mice. They were all cisplatin sensitive, anti-EGFR therapy resistant, and androgen irresponsive. Whole-genomic sequecing analysis revealed that transition mutations (C:G>T:A and T:A>C:G) were the most common substitution types in these cell lines, whereas ERCC5 , TP53 , PTH1 , CLTCL1 , NOTCH2 , MAP2K3 , CDK11A/B , USP6 , ADCH5 , BCLAF1 , CDKN2A , FANCD2 , HRAS , and NOTCH1 were the most frequently altered genes. Amplifications of MYC , PLAG1 , NCOA2 , RUNX1T1 , COX6C , and EGFR and losses of FBXW7 , TET2 , XPC , and FANCE were frequently observed in cell lines. The exomic variations between cell lines and their corresponding cancer tissues were highly consistent. Genetic variations were mainly involved in the MAPK, Jak-STAT, TGF-beta, Notch, and apoptosis signaling pathways. Conclusively, these panel of PSCC cell lines established in our laboratory harbor some common or specific biological characteristics and genomic variations, and they may serve as optimal models to investigate the molecular mechanisms underlying the progression, metastasis, relapses, and treatment resistance of PSCC and to develop effective treatment strategy.

Open article ↗



2018-03-21 | Neo-glans reconstruction for penile cancer: Description of the primary technique using autologous testicular tunica vaginalis graft

Partial penectomy (glansectomy with/or without distal corporectomy) is an acceptable alternative for smaller distal pT3 penile carcinoma lesions in highly motivated and compliant patients. The authors describe a novel technique of neo-glans reconstruction using a tunica vaginalis (TV) testis allograft. However, due to an unclear resection margin on final histology, the patient underwent re-do surgery with a neo-glans revision using the well-established mesh split-thickness skin graft (STSG) technique. The penile length was preserved and the penile and bulbar part of the urethra was additionally mobilised in order to obtain a natural and aesthetic result for the meatus.Neo-glans reconstruction with TV coverage may be another promising alternative, which certainly requires further evaluation. We believe that the donor-site associated morbidity is minimal when compared to other harvesting sites. However, this is just an assumption, because direct comparison data on grafting techniques and neo-glans reconstruction are not available. Nevertheless, we think that for re-do procedures a standardised approach using a STSG technique should be the treatment method of choice.

Open article ↗



proteins
2026-09-29 | HPV status and histopathological prognostic factors in penile squamous cell carcinoma.

Penile squamous cell carcinoma (PSCC) is a rare malignancy that may develop following persistent infection with human papillomavirus (HPV). The prognostic value of HPV status remains controversial. To evaluate the impact of p16 status, a surrogate marker of high-risk HPV-driven carcinogenesis, and selected histopathological features on survival outcomes in PSCC, and to assess their interrelationships. This retrospective single-center study included 87 patients treated for PSCC at Saint-Louis Hospital (Paris, France) between 2015 and 2024. Associations between p16 status and histopathological features (pT stage, pN stage, tumor grade, lymphovascular invasion, and perineural invasion) were assessed using Chi-squared tests. Their impact on disease-specific survival (DSS) and overall survival (OS) was analyzed using Kaplan-Meier curves and log-rank tests. Thirty-seven patients (43%) had p16-positive tumors. p16 status was not associated with tumor stage, nodal status, lymphovascular invasion, or perineural invasion. p16-positive tumors were significantly associated with higher histological grade (p < 0.001). Factors associated with poorer 3-year DSS included nodal involvement (54.4% vs 100%, p < 0.001), lymphovascular invasion (52.5% vs 90.9%, p = 0.024), and perineural invasion (59.9% vs 91.4%, p < 0.01). p16 status was not associated with DSS (p = 0.68). In this retrospective single-center cohort, p16 status was not significantly associated with DSS in univariate analysis. Nodal involvement, lymphovascular invasion, and perineural invasion were the variables most strongly associated with prognosis in the univariate analyses.

Open article ↗



2026-05-28 | Granulomatous posthitis caused by <i>Halicephalobus gingivalis</i> in association with penile squamous cell carcinoma in an equine: clinical and anatomopathological aspects

Penile and preputial squamous cell carcinomas are among the most common tumors in horses, and inflammation of the external genitalia caused by Halicephalobus gingivalis is an important differential diagnosis. H. gingivalis is a free-living nematode that causes fatal parasitic encephalitis in horses and humans and can eventually be diagnosed in the kidneys, lymph nodes, lungs, genital and ocular mucosa. The objective was to characterize clinical and pathological lesions caused by H. gingivalis infection in the prepuce with concomitant involvement of penile squamous cell carcinoma in an equine. A 15-year-old male Pampa horse with prepuce and penis ulcerated lesions had these surgically excised. Histopathological analysis revealed granulomatous posthitis with H. gingivalis intralesional and ulcerated penile squamous cell carcinoma. The animal had a satisfactory clinical and surgical evolution, and there was no recurrence of the lesions after a six-month follow-up period. Considerations regarding the route of infection, treatment, and zoonotic potential were highlighted, showing the importance of including this pathogen in the differential diagnosis of nodular lesions affecting the preputial and penile areas in horses.

Open article ↗



2026-04-06 | Clinical, epidemiological, and diagnostic aspects of erythroplasia of queyrat

BACKGROUND: Erythroplasia of Queyrat (ICD-10 code: D07.4) is an intraepithelial neoplasia affecting the glans penis and inner preputial leaf. It is classified as a squamous cell carcinoma in situ. However, available publications lack data on its prevalence across age groups. AIM: The work aimed to examine the clinical and epidemiological aspects of erythroplasia of Queyrat and assess the efficacy of various diagnostic approaches. METHODS: A retrospective, cross-sectional case history study in patients who sought medical advice for penile lesions of various origins (n = 327) and a prospective observational study in patients with erythroplasia of Queyrat (n = 49) were conducted. Toluidine blue staining, dermatoscopy, and cytological and histological examinations were used in the diagnosis of erythroplasia of Queyrat. Additionally, an ultrasound of the penis and inguinal lymph nodes, tests for sexually transmitted infections, and a transrectal prostate ultrasound were performed. RESULTS: The observational study in patients with erythroplasia of Queyrat revealed a trend towards younger onset. The majority of patients (30.61%) were aged 50–59 years, with the disease detected before the age of 29 in 12.24% of cases and at the age of 30–39 in 20.4% of cases. A total of 89.8% of patients saw physicians of various specialties (urologists, dermatovenerologists, oncologists, etc.), whereas 10.2% self-medicated. The time between the onset of penile rashes and seeking medical advice is particularly concerning, ranging from 1 week (4.0%) to more than 5 years (2.0%). Thus, patients with a disease duration of ≥ 1 year (12.1%) are at the highest risk of penile squamous cell carcinoma. The majority of patients with erythroplasia of Queyrat consult with a dermatovenerologist, with the final diagnosis made on the initial or follow-up visit in 93.87% of cases, indicating that dermatovenerologists are familiar with clinical signs and diagnostic approaches in this condition. CONCLUSION: This work addresses the gaps in the modern assessment of clinical and epidemiological aspects and diagnostic efficacy in patients with erythroplasia of Queyrat, facilitating the selection of effective therapeutic options.

Open article ↗



2026-03-25 | Locally Advanced Squamous Cell Carcinoma of the Penis- Case Report and Literature Review

Squamous cell carcinoma of the penis is a rare but aggressive tumor, the prognosis of which depends closely on the stage at diagnosis. Locally advanced forms pose a major therapeutic challenge, requiring multidisciplinary management. We report the case of a patient with advanced squamous cell carcinoma of the penis, detailing the diagnostic approach, treatment strategy, and outcome, while also discussing current data from the literature.

Open article ↗



2026-03-17 | Association of CCL21+ CAFs with B-cell recruitment and TLS maturation in penile squamous cell carcinoma.

Penile squamous cell carcinoma (PSCC) is an aggressive malignancy with a poor prognosis and limited therapeutic options. Tertiary lymphoid structures (TLSs) can support antitumour immunity, yet TLS maturation and maturation-associated stromal determinants in PSCC remain unclear. Here, we integrated hematoxylin and eosin (H&E) staining, multiplex immunohistochemical (mIHC) colocalization, spatial transcriptomics, single-cell RNA sequencing (scRNA-seq), and bulk RNA sequencing (bulk RNA-seq) to profile TLS maturity and TLS-associated stromal-immune features in PSCC. TLS maturity was quantified using an AUCell germinal centre-like signature, and the presence of mature TLSs (mTLSs) coincided with improved survival. We identified a CCL21+ CAF subset that was preferentially enriched in mTLSs, spatially concentrated in the mTLS-core and adjacent to B-cell-rich areas; mIHC further confirmed dense CCL21+ACTA2+ CAFs near CD20+ aggregates. Along an inferred iTLS-to-mTLS continuum, the abundance of CCL21+ CAFs increased, and the expression of chemokines increased. Spatial and transcriptomic analyses further linked B-cell chemotaxis- and activation-related signatures to the CCL21-CCR7 axis, accompanied by germinal centre-like B-cell features. Clinically, higher CCL21 expression, elevated CCL21+ CAF signature scores, and stronger CCL21-CCR7 signatures in B cells were associated with favourable outcomes. Together, these data suggest that CCL21+ CAFs or CCL21 are potential prognostic biomarkers for risk stratification and immune microenvironment profiling and highlight the CCL21-CCR7 axis as a candidate pathway for therapeutic modulation of TLS maturity in PSCC.

Open article ↗



antibodies
2026-09-22 | Reduced Nectin-4 expression in lymph node metastases of penile squamous cell carcinoma: a paired primary–metastatic analysis

Objective To evaluate Nectin-4 expression in primary and matched metastatic penile squamous cell carcinoma (PSCC) lesions and to assess its associations with clinicopathological features and survival outcomes. Methods We analyzed 123 patients with pathologically confirmed PSCC treated at our hospital between 2018 and 2024. Nectin-4 expression was assessed by immunohistochemistry using the H-score (0-300) in primary tumors and 30 matched lymph node metastases, and associations with pathological features, paired primary-metastatic differences, and survival outcomes were analyzed. Results Nectin-4 was widely expressed in PSCC. Higher Nectin-4 expression was observed in less aggressive tumors. Expression was higher in T1 than in T2 stage (95% CI 19.10-79.28; P < 0.01) and decreased from G1 to G3, with significant differences between G1 and G2 (95% CI 0.39-63.83; P = 0.047) and between G1 and G3 (95% CI 24.41-170.43; P = 0.009). Expression in primary tumors was not significantly associated with nodal status. In paired samples, lymph node metastases showed lower H-scores than their matched primary tumors (95% CI 3.52-72.82; P = 0.032). Low Nectin-4 expression was associated with shorter overall survival in Kaplan-Meier and univariable Cox analyses, but it was not independently associated with survival after multivariable adjustment. Conclusions Nectin-4 expression in PSCC is higher in early, better-differentiated tumors and lower in lymph node metastases. Low Nectin-4 expression was associated with poorer overall survival, although it was not an independent prognostic factor. These findings suggest that Nectin-4 may have prognostic relevance and potential value as a therapeutic target in PSCC.

Open article ↗



2026-09-20 | Current Management and Investigational Therapeutic Strategies in Penile Squamous Cell Carcinoma: A Narrative Review.

Penile squamous cell carcinoma (PSCC) is a rare and aggressive genitourinary malignancy requiring integrated multidisciplinary management. This narrative review provides an updated overview of the diagnostic and therapeutic pathway of PSCC from localized disease, where surgery remains the cornerstone of treatment, to locally advanced disease, where multimodal strategies integrating chemotherapy and radiotherapy with surgery are required, and finally to metastatic disease, where systemic therapy becomes the mainstay of treatment. Platinum-based chemotherapy remains the established systemic backbone for advanced PSCC, whereas immune checkpoint inhibitors, chemo-immunotherapy combinations, targeted therapies, antibody-drug conjugates, vaccines, and adoptive cellular therapies represent investigational strategies supported by preliminary evidence. Although these approaches have shown early signals of activity, their routine integration into clinical practice remains limited by small and heterogeneous studies, the lack of definitive randomized evidence, and the need for prospective validation in well-defined clinical and molecular subgroups. The aim of this review is therefore to provide a stage-adapted and multidisciplinary overview of therapeutic strategies for the contemporary management of PSCC.

Open article ↗



2026-09-18 | MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis.

Emerging evidence suggests that combinations of antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) may be effective for advanced penile squamous cell carcinoma (PSCC). These findings support the translation of this strategy into the neoadjuvant setting, offering a novel approach for patients with locally advanced or regionally metastatic disease who have limited treatment options. This single-center, prospective, single-arm, phase II trial evaluates the efficacy and safety of neoadjuvant Becotatug Vedotin plus Pucotenlimab in EGFR-expressing PSCC patients with challenging penile preservation or regional lymph node metastasis. Utilizing a Simon's two-stage design, the primary endpoint is the investigator-assessed R0 resection rate. Secondary endpoints include the downstaging rate, objective response rate (ORR), pathological complete response (pCR) rate, major pathological response (MPR) rate, tumor regression grade (TRG), event-free survival (EFS), disease-free survival (DFS), and organ‑sparing rate. The study plans to enroll 60 patients with EGFR-expressing PSCC. Clinical trial registration: www.clinicaltrials.gov identifier is NCT07518979.

Open article ↗



2026-09-17 | Pre-existing immunity and hrHPV status determine immunotherapy response in advanced penile cancer: biomarkers and overall survival in the PERICLES trial.

Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis. Patients were treated with atezolizumab monotherapy (n=12) or atezolizumab in combination with radiotherapy (n=20, 33 fractions of 1.5-1.8 Gy) for locoregional disease control. Comprehensive analysis of baseline tumor tissue (n=28/31) was performed using bulk RNA sequencing, immunohistochemistry and multiplex immunofluorescence. Additionally, spatial transcriptomics (n=9) was conducted to further explore functionality and (co-)localization of immune cell subsets. With extended follow-up (median: 38 months), landmark 2-year OS and PFS in the full study cohort was 18.8% (95% CI, 9.1-38.6) and 12.5% (95% CI, 5.0-31.3), respectively. High-risk human papillomavirus (hrHPV)-positive tumors were enriched for IFN-γ and IFN-α signatures, potentially explaining the improved PFS and OS observed in this subgroup. Both stromal CD68+ myeloid cell density and intratumoral CD8+PD1+ T-cell density were associated with non-progression at 1 year. Increased intratumoral CD8+PD1+ T-cell density was also associated with improved PFS and OS, with consistent findings in the hrHPV-positive subgroup. Spatial transcriptomics identified these CD8+ T cells as tissue-resident cytotoxic effector cells co-expressing checkpoint molecules (LAG3 and TIGIT), chemokines (CCL4 and CXCL13), and cytotoxic molecules (PRF1 and GZMB). Interrogation of the penile cancer immune microenvironment highlights CD8+PD1+ T-cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.

Open article ↗



2026-08-25 | Multifocal HPV16-positive squamous cell carcinomas in CTLA-4 haploinsufficiency: expanding the spectrum of virus-associated malignancies.

Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) haploinsufficiency is an inborn error of immunity characterized by immune dysregulation, autoimmunity, lymphoproliferation, and an increased risk of malignancy. While susceptibility to oncogenic viral infections has been proposed, the relationship between CTLA-4 haploinsufficiency and human papillomavirus (HPV)-driven carcinogenesis remains poorly characterized. We describe a patient with CTLA-4 haploinsufficiency who developed multiple HPV-associated malignancies. Clinical, pathological, virological, and genetic data were reviewed. Germline genetic testing was performed using whole-exome sequencing, and HPV DNA analysis was conducted on available tumor specimens. A man with a history of alopecia totalis and autoimmune thyroiditis developed five distinct malignancies by the age of 50 years, including Epstein-Barr virus (EBV)-associated gastric Hodgkin lymphoma, cutaneous squamous cell carcinoma (SCC), and three independent HPV16-positive SCCs involving the oral cavity, anus, and penis. Germline testing identified CTLA-4 haploinsufficiency caused by a likely pathogenic CTLA4 variant, c.406C > T (p.Pro136Ser). No additional germline variants associated with hereditary cancer predisposition were detected. HPV DNA analysis demonstrated HPV16 positivity in all three mucosal SCCs. This case expands the spectrum of malignancies associated with CTLA-4 haploinsufficiency and suggests that persistent high-risk HPV infection may represent an underrecognized complication of this disorder. The occurrence of three independent HPV16-positive SCCs raises the possibility that CTLA-4 deficiency predisposes to HPV-driven carcinogenesis and supports further investigation of HPV surveillance and cancer prevention strategies in affected individuals.

Open article ↗



other
2026-07-27 | Vaccine Therapy for the Management of Penile Cancer: Evidence, Opportunities and Challenges.

Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited therapeutic options in advanced and recurrent diseases. Advanced PSCC is typically managed with multimodal therapy, including neoadjuvant chemotherapy or chemoradiation followed by surgery; however, durable responses remain uncommon, and outcomes after recurrence are poor. Cancer vaccines represent a promising immunotherapeutic strategy, as these treatments induce tumor-specific immunity and heightened immune surveillance against penile cancer cells. While therapeutic cancer vaccines have not yet demonstrated consistent clinical efficacy as monotherapy in PSCC, their integration with complementary immune-modulating approaches, particularly immune checkpoint blockade, represents a rational strategy to enhance antitumor immunity. This review summarizes the rationale for vaccine development in PSCC, with emphasis on HPV-derived antigens, neoantigens, and emerging tumor-associated targets. We examine major vaccine platforms, including viral-vector, peptide-based, nucleic acid, and dendritic cell-based approaches. We also discuss how spatial transcriptomics, single-cell RNA sequencing, artificial intelligence-assisted antigen prediction, and nanotechnology-enhanced delivery systems may support future personalized vaccine development. Overall, therapeutic vaccines remain investigational in PSCC but may become relevant within biomarker-driven, combination-based immunotherapy strategies.

Open article ↗



2025-12-18 | Prevalence and time trends of human papillomavirus in penile cancer over 26 years-A comprehensive study of 1040 penile cancer cases from Denmark.

Penile cancer is rare. It has been suggested that approximately half are human papillomavirus (HPV) associated, but large-scale studies on HPV prevalence and time trends are limited. We aimed to examine the high-risk HPV (hrHPV) prevalence in a large single-country study of penile squamous cell carcinomas (SCC) during a 26-year period. From the nationwide Danish Pathology Register, we identified all penile SCCs diagnosed during the period 1995-2020 at hospitals covering most regions in Denmark. Histologic slides were evaluated by expert pathologists, and archived tumor tissue was tested for the presence of HPV DNA using the INNO-LiPA assay. We assessed the overall and type-specific HPV prevalence according to calendar period, age, and histology, and estimated the annual percentage change (EAPC) of hrHPV positivity over the entire study period. We included 1040 penile SCCs. The overall HPV prevalence was 54.5% and the hrHPV prevalence was 50.4%. We observed no change in the prevalence of hrHPV over time (EAPC = -0.03% [95% confidence interval: -0.91; 0.85]). HPV16 was the most prevalent genotype (41.1%), and 50.0% of the penile SCCs had an HPV type that would be covered by the nine-valent HPV vaccine (HPV6/11/16/18/31/33/45/52/58). Penile SCCs with HPV-associated histological features had the highest hrHPV prevalence, particularly tumors exhibiting basaloid features (81.8%-87.7%). In this large population-based study, covering most regions in Denmark, we found no substantial change in hrHPV prevalence during 1995-2020. Our findings suggest that prophylactic vaccination with the nine-valent HPV vaccine could prevent a considerable part of penile SCCs in Denmark.

Open article ↗



2025-09-27 | Evaluating the Evolving Treatment Landscape of Systemic Therapies in Penile Cancer.

Penile squamous cell carcinoma (PSCC) represents a malignancy with low incidence. Despite advances in chemotherapy-based management, outcomes for patients with locally advanced and metastatic disease remain poor, with 5-year survival rates of 51% and 9%, respectively. Early diagnosis is crucial, yet psychosocial/structural barriers often delay it. Treatment strategies are stage-dependent, ranging from organ-sparing surgery and targeted radiotherapy for early-stage disease to cisplatin-based chemotherapy for locally advanced and metastatic cases. However, systemic therapies provide modest survival benefits and can expose the patient to unnecessary toxicities. Immunotherapy has emerged as a promising area, given the high expression of PD-L1 in PSCC and the significant proportion of HPV-driven tumors. Although initial results from immunotherapy-based trials are limited, preliminary trials such as HERCULES, ALPACA, PULSE, and PERICLES aim to define their role better. Similarly, combination regimens utilizing toripalimab in combination with nimotuzumab and taxane-based chemotherapy (TNT) followed by consolidative surgery are currently underway. Furthermore, the development of therapeutic HPV vaccines offers a novel strategy to enhance local antitumor immunity. Antibody-drug conjugates (ADCs) targeting HER-2, Trop-2, and Nectin-4 antigens represent another evolving therapeutic avenue that has shown preliminary promising results. As the landscape of penile cancer treatment continues to grow, incorporating these novel strategies could further improve survival outcomes and/or offer improved quality of life. This review provides a comprehensive overview of emerging systemic therapies in PSCC, underscoring ongoing research efforts to address unmet needs.

Open article ↗



2025-09-05 | Etiologic fraction of HPV-attributed anal and penile squamous cell carcinoma: study in specialized hospitals, Sri Lanka

Introduction The Human Papilloma Virus (HPV) infection is known to cause anogenital cancers. Male HPV prevalence and population-attributable risk (PAR)are important to plan future HPV preventive strategies for HPV-driven anogenital cancers in males. Methods A hospital-based case-control study was carried out to determine the etiologic fraction attributed to HPV-driven anal and penile(anogenital) cancers among male patients presenting to tertiary care hospitals in Gampaha district and Apeksha Hospital (cancer specialized), Sri Lanka and to calculate PAR percentage on anogenital SCC among the study population where HPV prevalence was 5.7%. New or already diagnosed patients for anal and penile SCC who reported to selected hospitals from August 2022 to June 2023 were recruited for data and specimen collection. A sample size of 20 cases and 80 controls were selected, with four controls chosen per case from sexually active, clinically normal men aged 20-70 years residing in the Gampaha district. Additional etiological factors that were checked included the presence of sexually transmitted infections, phimosis, anogenital injury, and the use of tobacco, alcohol or illegal drugs. The chi-square test was used at the level p<0.05 significance. Bivariable and logistic regression analyses were used to calculate odds ratios (ORs). Results A significantly associated factor for getting anal and penile SCC was HPV infection (p<0.001; adjusted OR: 27.7; 95% CI: 4.3,177.8).For any HPV genotype & high-risk HPV genotype, prevalence was 55% & 50% among cases and 5% & 2.5% among controls respectively. Assuming prevalence among controls as the population prevalence, the calculated PAR% was 62.2% for any HPV genotype and 33% for the HPV 16 HR genotype. Conclusions Sixty-two per cent of the anal and penile SCCs were attributed to any HPV genotype and one-third of anal and penile SCCs can be prevented by introducing HPV 16 genotype-containing vaccine to male.

Open article ↗



2025-05-28 | Effect of exosome-derived lncRNA on MAL + CTL apoptosis in remodeling of the immune microenvironment in HPV + penile squamous cell carcinoma.

e17022 Background: Patients with HPV + PSCC have a poor prognosis, and the immune escape mechanisms remain a major challenge in improving clinical outcomes. This study aims to investigate the role of exosome-derived long non-coding RNAs (lncRNAs) in modulating the immune microenvironment, particularly through their interaction with MAL + CTLs in HPV + PSCC. Methods: We collected tumor samples from HPV + PSCC patients and performed scRNA-seq to analyze the distribution and functional state of immune cells within the tumor microenvironment. Spatial transcriptomics were employed to explore the spatial localization of Tregs and CTLs within the tumor. Exosomes were isolated from the culture media of Treg cells and analyzed for the presence of lncRNAs. Additionally, the interaction between exosome-derived lncRNAs and miRNAs, particularly hsa-miR-619-3p, was examined in vitro. The impact of exosome-derived lncRNAs on MAL + CTL apoptosis was assessed using flow cytometry and apoptosis assays. Results: Our clinical data and scRNA-seq analysis revealed that HPV + PSCC tumors are characterized by an increased proportion of Treg cells and a decreased presence of CD8 + CTLs compared to HPV- PSCC or normal tissues. Importantly, we observed a significant correlation between the number of Tregs and the severity of immune suppression in HPV + PSCC. Spatial transcriptomics further revealed that Tregs were predominantly located in close proximity to CD8 + CTLs within the tumor microenvironment, suggesting potential interactions between these cell populations. Interestingly, exosome isolation from Tregs confirmed the presence of exosome-derived lncRNAs, which were shown to significantly alter the miRNA profile in surrounding immune cells. Specifically, we identified that exosome-derived lncRNAs from Tregs bound to hsa-miR-619-3p, a miRNA previously linked to T-cell dysfunction and immune evasion. We further demonstrated that this interaction led to an increase in MAL expression in CTLs, which in turn triggered their apoptosis. Flow cytometry analysis revealed that exposure to exosome-derived lncRNAs from Tregs resulted in a significant increase in MAL + CTLs and a concomitant increase in CTL apoptosis. Besides, the in vivo experiments using HPV + PSCC xenografts in mice showed that Treg-derived exosomes significantly impaired anti-tumor immunity, leading to increased tumor growth and reduced CTL infiltration in the tumor. Importantly, inhibition of MAL expression in CTLs by RNA interference rescued CTL function and partially restored anti-tumor immunity, confirming the pivotal role of MAL + CTLs in immune suppression. Conclusions: Our findings reveal a novel mechanism of immune evasion in HPV + PSCC, where Tregs secrete exosome-derived lncRNAs that interact with miR-619-3p to upregulate MAL expression in CTLs, leading to their apoptosis.

Open article ↗



small molecules
2026-09-08 | Epidemiological trends in penile cancer and the evolving role of dynamic sentinel lymph node biopsy.

Penile cancer (PeCa) is a rare but aggressive malignancy with growing global incidence. The most influential prognostic factor in PeCa is the presence of nodal metastasis. Current imaging modalities lack the diagnostic accuracy to reliably detect micro-metastasis in PeCa. Since 2015, Dynamic Sentinel Lymph Node Biopsy (DSLNBx) emerged as a means of accurately detecting nodal metastases in PeCa. The impact of DSLNBx on overall and cancer-specific survival years remains to be established in the Irish population. Population based data was obtained from The National Cancer Registry of Ireland (NCRI) on all patients diagnosed with PeCa between 1994 and 2021. Log-rank Mantel-Cox analysis was applied to assess survival benefit associated with DSLNBx. A total of 866 patients were diagnosed with PeCa in Ireland between 1994 and 2021 with population standardized incidence incrementing from 1.68 to 2.80 cases/100,000 males/year during this period. The most common histological subtype was squamous cell carcinoma (92.8%) followed by melanoma (2.7%), basal cell carcinoma (0.7%). Surgical excision constituted mainstay treatment (86.2%). DSLNBx was performed in 8% of cases of which 13% had node positive disease. Those who underwent DSLNBx were found to have a statistically significant increase in overall survival rate, χ2 (1) = 4.067, P = 0.044. Cancer specific survival rate correlated positively in those who underwent DSLNBx also, but this did not reach statistical significance. PeCa has growing incidence in Ireland. DSLNBx offers a means of accurately assessing presence of nodal metastasis whilst incurring minimal morbidity which has been associated with improved overall survival on univariate analysis.

Open article ↗



2026-09-07 | Apatinib monotherapy for pretreated advanced squamous cell carcinoma of the penis: a phase 2 trial.

Treatment options for patients with advanced penile squamous cell carcinoma who have disease progression on systemic chemotherapy are scarce. Antiangiogenic drugs have shown antitumor effects in case series. This phase 2 trial evaluated the activity and safety of apatinib (a Vascular Endothelial Growth Factor (VEGF) receptor inhibitor) in such patients. This investigator-initiated, single-arm, phase 2 trial was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN000021849) and performed at a tertiary cancer center in Shanghai, China. Eligible patients had histologically confirmed penile squamous cell carcinoma, were not candidates for surgery with curative intent, had measurable disease, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, pretreated with one or more kinds of systemic treatment. Patients were prescribed oral apatinib 500 mg daily with the option of dose reduction to manage adverse events. The primary endpoint was the investigator-assessed overall response rate (ORR) assessed in all patients who received at least one dose of study drug. Between 2016 and 2023, we enrolled 23 patients, all of whom received at least one dose of study treatment. Of the 23 patients, 16 had an ECOG performance status of 2. Only 6 patients had human papillomavirus-positive tumors. Five patients had a partial response (ORR = 22% [95% CI, 10%-42%]). The median progression-free survival was 3.8 months, and median overall survival was 7.2 months. Treatment-related adverse events of grade 3 or worse occurred in 7 (30%) of 23 patients. The most common grade 3 or 4 treatment-related adverse events were hand-foot syndrome (13%), hypertension (9%), and increase in serum alanine aminotransferase (9%). Apatinib in pretreated advanced penile cancer showed limited efficacy with a manageable safety profile. UMIN000021849.

Open article ↗



2026-08-26 | Assessment of EGFR and HER2 expression in penile cancer as potential therapeutic targets.

Penile cancer (PC) is a rare but aggressive malignancy with limited systemic treatment options, particularly in advanced stages. Targeted therapies against receptor tyrosine kinases such as EGFR and HER2 have demonstrated clinical benefit in other cancer types, yet their role in PC remains poorly defined. Understanding their expression patterns in primary tumors and metastases is essential for identifying new therapeutic avenues. In this study, we aimed to systematically assess the expression of EGFR and HER2 in a large multicenter PSCC cohort and evaluate their potential relevance not only as therapeutic targets but also as prognostic biomarkers. In addition, we analyzed possible correlations with key clinicopathological features, including HPV status, tumor stage and histological subtype. Among 208 patients, moderate to strong EGFR expression was detected in 27.0% of primary tumors and 29.0% of metastases, with HER2 overexpression observed in 7.0% and 21.4%, respectively. EGFR expression was significantly higher in HPV-negative tumors and associated with reduced overall survival. In contrast, HER2 was more frequently overexpressed in HPV-positive and basaloid tumors without prognostic significance. Expression patterns of both markers were largely homogeneous within primary tumors but showed partial discordance between primary and metastatic lesions. EGFR and HER2 are variably expressed in PC, with EGFR displaying potential as a prognostic marker. These findings suggest that both receptors may serve as therapeutic targets in certain patients, particularly if confirmed in metastases. Future research should integrate molecular profiling to refine biomarker-based stratification and guide the use of targeted therapies in this rare but challenging cancer.

Open article ↗



2026-08-24 | Randomized trial of adjuvant 5-FU-platinum vs paclitaxel-platinum for high-risk penile cancer.

Adjuvant chemotherapy is recommended for high-risk penile squamous cell carcinoma (SCC) metastatic to lymph nodes based on retrospective data, but no randomized trials have been conducted. We compared 5-fluorouracil (5-FU)-platinum with paclitaxel-platinum in this setting. In this open-label, randomized trial at an Indian tertiary cancer center, men <70 years with resected node-positive penile SCC and ≥1 high-risk feature (perinodal extension, pelvic node involvement, >1 inguinal nodes, or ≥ 4 cm node) were assigned 1:1 to four 3-weekly cycles of 5-FU-platinum or paclitaxel-platinum, followed by cisplatin-based chemoradiotherapy. Primary endpoint was disease-free survival (DFS). Secondary endpoints were overall survival (OS), toxicity, and quality-of-life (QoL). Between 2017 and 2024, 49 patients were randomized (5-FU-platinum: 25, paclitaxel-platinum: 24). At a median follow-up of 69 months, median DFS was 12.4 months (95% CI, 3.38-NR) vs 19.6 months (95% CI, 5.82-NR) (HR, 1.16; 95% CI, 0.55-2.45; P = 0.686) and median OS was 21.3 vs 36.7 months (HR, 1.13; 95% CI, 0.52-2.44; P = 0.754) for 5-FU-platinum and paclitaxel-platinum, respectively. Grade ≥3 toxicities occurred in 77.3% vs 40.9% (P = 0.014), grade ≥3 hematologic toxicities in 54.5% vs 4.5% (P < 0.001), and hospitalization for toxicity in 45.5% vs 9.1% (P = 0.016). Completion of all planned cycles was higher with paclitaxel-platinum (83.3% vs 48%; P = 0.009). QoL and sexual health were similar between the two treatment arms. Adjuvant paclitaxel-platinum was associated with improved tolerability compared with fluorouracil-platinum in high-risk node positive penile cancer and warrants further evaluation in larger multicenter studies. Early termination precluded definitive efficacy comparisons. Clinical Trials Registry of India (CTRI/2016/12/007567). This work was supported by Indian Cooperative Oncology Network and Tata Memorial Center.

Open article ↗



2026-08-07 | Intratumoral para-toluenesulfonamide as a tumor-ablative therapy for equine cutaneous tumors: a case series of three horses.

Equine neoplasia, including sarcoids, melanomas, and squamous cell carcinomas, presents therapeutic challenges due to recurrence and limitations of conventional treatments. Para-toluenesulfonamide (p-TLS) is a tumor-ablating agent that is associated with localized tumor necrosis and subsequent lesion resolution. It has been evaluated in human clinical settings as an intratumoral treatment of malignant airway obstruction caused by non-small cell lung cancer. This study aimed to describe the clinical outcomes and tolerability of intratumoral p-TLS in equine neoplasia. Three equine cases, including a fibroblastic sarcoid, perianal melanoma, and penile squamous cell carcinoma, were treated. The fibroblastic sarcoid and penile squamous cell carcinoma achieved complete response. The melanoma fulfilled the criteria for partial response at the protocol-defined clinical evaluation timepoint and subsequently demonstrated complete clinical resolution during follow-up. All cases demonstrated a consistent pattern of response characterized by tumor necrosis, sloughing, and subsequent wound healing with complete re-epithelialization. Local adverse effects were limited to transient inflammation and mild discomfort, which were effectively managed with supportive care. No severe adverse events or tumor recurrence were observed during the follow-up period ranging from 120 days to 15 months. These findings suggest that p-TLS may represent a feasible, highly minimally invasive intratumoral therapeutic approach for equine neoplasia and support further evaluation.

Open article ↗



cell therapies
2022-12-15 | Establishment and Characterization of Advanced Penile Cancer Patient-derived Tumor Xenografts: Paving the Way for Personalized Treatments.

Systemic treatments for penile squamous cell carcinoma (pSCC) are toxic and inefficient. Patient-based preclinical models are essential to study novel treatments. To establish a library of patient-derived tumor xenograft (PDX) models of human papillomavirus-positive (HPV+) and -negative (HPV-) pSCC and characterize these at the genomic and histological levels. Eighteen tumor samples from 14 patients with recurrent or metastatic pSCC were implanted in nude mice. A biobank of PDX tumors was established after passaging of patient samples (F0) for three generations (F1, F2, F3) and was characterized using histopathology and targeted next-generation sequencing (tNGS). Single-nucleotide polymorphism fingerprinting was used to confirm PDX genealogy. The engraftment rate, overall growth rate, and pSCC histomorphology were checked for each PDX generation. Staining for p40 (a pSCC marker) and p16 (a surrogate for HPV infection) was performed for F0 samples. The mutational profile according to a validated panel of 96 cancer genes was determined for F0 and F3 samples and compared to a larger tNGS database. Including a previously established pilot model, 11 out of 18 tumor samples (61%) successfully engrafted in F1. The mean time from implantation in F1 to completion of F3 was 36 wk (standard deviation 18). Histological fidelity was demonstrated across generations. The patient mutational profiles were preserved in F3 and were representative of 277 pSCC samples in the Foundation Medicine database. The rapid progression of pSCC in patients from our selected high-risk cohort impeded the use of PDXs as avatars. We successfully established the first library of 11 PDX models of HPV- and HPV+ pSCC. Our PDX models showed high engraftment rates and histological and genomic fidelity to the tumor tissue of origin. These models may help in paving the way towards the development of novel treatments. We established 11 animal models based on tumor tissue from patients with penile cancer. These models could play a vital role in selection of novel treatments according to genetic mutations. In the future, therapies with confirmed preclinical effects may have a profound impact on the development of personalized treatments in penile cancer.

Open article ↗



2021-06-09 | Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients.

Penile cancer is a rare but highly lethal cancer, and therapeutic options for patients presenting with lymph nodal disease are very limited. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) was shown to provide durable objective response in patients with metastatic melanoma and TIL have been expanded from solid tumors at rates between 70 and 90% depending on the specific diagnosis. We evaluated whether TIL could be expanded from surgical specimens of patients with penile cancer. Tumor samples from metastatic lymph nodes obtained at the time of inguinal lymph node dissection were collected, minced into fragments, placed in individual wells of a 24-well plate, and propagated in high dose IL-2 for four weeks. The phenotype of expanded TILs was assessed by flow cytometry and their anti-tumor reactivity was assessed by IFN-γ ELISA. TIL were expanded from 11 out of 12 (91.6%) samples of metastatic lymph nodes. Expanded TIL were predominantly CD3+ (mean 67.5%, SD 19.4%) with a mean of 46.8% CD8+ T cells (SD 21.1%). Five out of 11 samples (45.4%) from expanded TIL secreted IFN-γ in response to autologous tumor. TIL expansion and phenotype of expanded T cell lymphocytes were independent of previous HPV infection and treatment with neoadjuvant chemotherapy. This is the first report demonstrating successful expansion of tumor-reactive TIL from penile cancer patients, which support development of ACT strategies using TIL for the treatment of advanced and recurrent penile cancer.

Open article ↗



2019-09-01 | Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer

Treatment of locoregionally advanced penile squamous cell carcinoma (LAPSCC) is challenging. The exact role (in terms of oncological benefit) of extensive surgery is not well established. Moreover, surgery invariably leads to large defects requiring reconstructive surgery. Rectus abdominis myocutaneous (RAM) and abdominal advancement flaps have an independent and constant blood supply, are easily harvested, and provide substantial skin coverage and soft tissue.To determine the surgical and oncological outcomes in patients with LAPSCC undergoing surgical resection with RAM flaps.From 2002 to 2016, a multi-institutional database identified 15 LAPSCC patients undergoing flap reconstructions.Local surgical resection with RAM or abdominal advancement flap reconstruction.Perioperative and pathologic data were collected. Postoperative complications were identified using the Clavien-Dindo classification for surgical complications.Fifteen patients (median age 61 yr) were treated, ten with curative intent. Thirteen patients received induction chemotherapy. Thirteen of the 15 patients (87%) experienced wound complications, including five Clavien-Dindo grade III complications. In 11/15 patients (73%), the disease recurred (median recurrence-free interval 106 d). The majority of recurrences (91%) were locoregional, and in four cases the patient also had lesions in distant organs. Ten of the 15 patients (67%) died of their disease. The overall median follow-up interval was 10.5 mo. The study was limited by its retrospective design, the absence of quality-of-life measurements, and the cohort size.The results of this study show that surgical resection with reconstruction is associated with a risk of perioperative complications, including high-grade Clavien-Dindo complications. With a cure rate of 27%, surgery must be carefully considered and there is a need for alternative treatments. Lack of robust quality-of-life-data is also a serious shortcoming in the decision process for this patient category.Surgery in locoregionally advanced penile cancer has a low cure rate. Reconstruction of defects is surgically feasible, albeit with a high risk of complications. Furthermore, decision-making lacks robust data on quality of life after surgery.

Open article ↗



2018-06-07 | Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines

Abstract Cell line models are essential tools to study the molecular mechanisms underlying tumor initiation and progression. There are limited treatment options for penile squamous cell carcinoma (PSCC), accounting for 1–2% of male tumors in developing countries, and limited progress in preclinical research in PSCC due to lacking available models with identified genomic characteristics. Here, biological and molecular characteristics and whole-genomic alterations were analyzed in a panel of PSCC cell lines newly established in our laboratory. These cell lines were all human papillomavirus (HPV)-negative, epithelial-like, immortalized, and tumorigenic in nude mice, whereas they displayed different proliferation, migration and invasion capacities in vitro, and tumorigenic ability in nude mice. They were all cisplatin sensitive, anti-EGFR therapy resistant, and androgen irresponsive. Whole-genomic sequecing analysis revealed that transition mutations (C:G>T:A and T:A>C:G) were the most common substitution types in these cell lines, whereas ERCC5 , TP53 , PTH1 , CLTCL1 , NOTCH2 , MAP2K3 , CDK11A/B , USP6 , ADCH5 , BCLAF1 , CDKN2A , FANCD2 , HRAS , and NOTCH1 were the most frequently altered genes. Amplifications of MYC , PLAG1 , NCOA2 , RUNX1T1 , COX6C , and EGFR and losses of FBXW7 , TET2 , XPC , and FANCE were frequently observed in cell lines. The exomic variations between cell lines and their corresponding cancer tissues were highly consistent. Genetic variations were mainly involved in the MAPK, Jak-STAT, TGF-beta, Notch, and apoptosis signaling pathways. Conclusively, these panel of PSCC cell lines established in our laboratory harbor some common or specific biological characteristics and genomic variations, and they may serve as optimal models to investigate the molecular mechanisms underlying the progression, metastasis, relapses, and treatment resistance of PSCC and to develop effective treatment strategy.

Open article ↗



2018-03-21 | Neo-glans reconstruction for penile cancer: Description of the primary technique using autologous testicular tunica vaginalis graft

Partial penectomy (glansectomy with/or without distal corporectomy) is an acceptable alternative for smaller distal pT3 penile carcinoma lesions in highly motivated and compliant patients. The authors describe a novel technique of neo-glans reconstruction using a tunica vaginalis (TV) testis allograft. However, due to an unclear resection margin on final histology, the patient underwent re-do surgery with a neo-glans revision using the well-established mesh split-thickness skin graft (STSG) technique. The penile length was preserved and the penile and bulbar part of the urethra was additionally mobilised in order to obtain a natural and aesthetic result for the meatus.Neo-glans reconstruction with TV coverage may be another promising alternative, which certainly requires further evaluation. We believe that the donor-site associated morbidity is minimal when compared to other harvesting sites. However, this is just an assumption, because direct comparison data on grafting techniques and neo-glans reconstruction are not available. Nevertheless, we think that for re-do procedures a standardised approach using a STSG technique should be the treatment method of choice.

Open article ↗



proteins
2026-09-29 | HPV status and histopathological prognostic factors in penile squamous cell carcinoma.

Penile squamous cell carcinoma (PSCC) is a rare malignancy that may develop following persistent infection with human papillomavirus (HPV). The prognostic value of HPV status remains controversial. To evaluate the impact of p16 status, a surrogate marker of high-risk HPV-driven carcinogenesis, and selected histopathological features on survival outcomes in PSCC, and to assess their interrelationships. This retrospective single-center study included 87 patients treated for PSCC at Saint-Louis Hospital (Paris, France) between 2015 and 2024. Associations between p16 status and histopathological features (pT stage, pN stage, tumor grade, lymphovascular invasion, and perineural invasion) were assessed using Chi-squared tests. Their impact on disease-specific survival (DSS) and overall survival (OS) was analyzed using Kaplan-Meier curves and log-rank tests. Thirty-seven patients (43%) had p16-positive tumors. p16 status was not associated with tumor stage, nodal status, lymphovascular invasion, or perineural invasion. p16-positive tumors were significantly associated with higher histological grade (p < 0.001). Factors associated with poorer 3-year DSS included nodal involvement (54.4% vs 100%, p < 0.001), lymphovascular invasion (52.5% vs 90.9%, p = 0.024), and perineural invasion (59.9% vs 91.4%, p < 0.01). p16 status was not associated with DSS (p = 0.68). In this retrospective single-center cohort, p16 status was not significantly associated with DSS in univariate analysis. Nodal involvement, lymphovascular invasion, and perineural invasion were the variables most strongly associated with prognosis in the univariate analyses.

Open article ↗



2026-05-28 | Granulomatous posthitis caused by <i>Halicephalobus gingivalis</i> in association with penile squamous cell carcinoma in an equine: clinical and anatomopathological aspects

Penile and preputial squamous cell carcinomas are among the most common tumors in horses, and inflammation of the external genitalia caused by Halicephalobus gingivalis is an important differential diagnosis. H. gingivalis is a free-living nematode that causes fatal parasitic encephalitis in horses and humans and can eventually be diagnosed in the kidneys, lymph nodes, lungs, genital and ocular mucosa. The objective was to characterize clinical and pathological lesions caused by H. gingivalis infection in the prepuce with concomitant involvement of penile squamous cell carcinoma in an equine. A 15-year-old male Pampa horse with prepuce and penis ulcerated lesions had these surgically excised. Histopathological analysis revealed granulomatous posthitis with H. gingivalis intralesional and ulcerated penile squamous cell carcinoma. The animal had a satisfactory clinical and surgical evolution, and there was no recurrence of the lesions after a six-month follow-up period. Considerations regarding the route of infection, treatment, and zoonotic potential were highlighted, showing the importance of including this pathogen in the differential diagnosis of nodular lesions affecting the preputial and penile areas in horses.

Open article ↗



2026-04-06 | Clinical, epidemiological, and diagnostic aspects of erythroplasia of queyrat

BACKGROUND: Erythroplasia of Queyrat (ICD-10 code: D07.4) is an intraepithelial neoplasia affecting the glans penis and inner preputial leaf. It is classified as a squamous cell carcinoma in situ. However, available publications lack data on its prevalence across age groups. AIM: The work aimed to examine the clinical and epidemiological aspects of erythroplasia of Queyrat and assess the efficacy of various diagnostic approaches. METHODS: A retrospective, cross-sectional case history study in patients who sought medical advice for penile lesions of various origins (n = 327) and a prospective observational study in patients with erythroplasia of Queyrat (n = 49) were conducted. Toluidine blue staining, dermatoscopy, and cytological and histological examinations were used in the diagnosis of erythroplasia of Queyrat. Additionally, an ultrasound of the penis and inguinal lymph nodes, tests for sexually transmitted infections, and a transrectal prostate ultrasound were performed. RESULTS: The observational study in patients with erythroplasia of Queyrat revealed a trend towards younger onset. The majority of patients (30.61%) were aged 50–59 years, with the disease detected before the age of 29 in 12.24% of cases and at the age of 30–39 in 20.4% of cases. A total of 89.8% of patients saw physicians of various specialties (urologists, dermatovenerologists, oncologists, etc.), whereas 10.2% self-medicated. The time between the onset of penile rashes and seeking medical advice is particularly concerning, ranging from 1 week (4.0%) to more than 5 years (2.0%). Thus, patients with a disease duration of ≥ 1 year (12.1%) are at the highest risk of penile squamous cell carcinoma. The majority of patients with erythroplasia of Queyrat consult with a dermatovenerologist, with the final diagnosis made on the initial or follow-up visit in 93.87% of cases, indicating that dermatovenerologists are familiar with clinical signs and diagnostic approaches in this condition. CONCLUSION: This work addresses the gaps in the modern assessment of clinical and epidemiological aspects and diagnostic efficacy in patients with erythroplasia of Queyrat, facilitating the selection of effective therapeutic options.

Open article ↗



2026-03-25 | Locally Advanced Squamous Cell Carcinoma of the Penis- Case Report and Literature Review

Squamous cell carcinoma of the penis is a rare but aggressive tumor, the prognosis of which depends closely on the stage at diagnosis. Locally advanced forms pose a major therapeutic challenge, requiring multidisciplinary management. We report the case of a patient with advanced squamous cell carcinoma of the penis, detailing the diagnostic approach, treatment strategy, and outcome, while also discussing current data from the literature.

Open article ↗



2026-03-17 | Association of CCL21+ CAFs with B-cell recruitment and TLS maturation in penile squamous cell carcinoma.

Penile squamous cell carcinoma (PSCC) is an aggressive malignancy with a poor prognosis and limited therapeutic options. Tertiary lymphoid structures (TLSs) can support antitumour immunity, yet TLS maturation and maturation-associated stromal determinants in PSCC remain unclear. Here, we integrated hematoxylin and eosin (H&E) staining, multiplex immunohistochemical (mIHC) colocalization, spatial transcriptomics, single-cell RNA sequencing (scRNA-seq), and bulk RNA sequencing (bulk RNA-seq) to profile TLS maturity and TLS-associated stromal-immune features in PSCC. TLS maturity was quantified using an AUCell germinal centre-like signature, and the presence of mature TLSs (mTLSs) coincided with improved survival. We identified a CCL21+ CAF subset that was preferentially enriched in mTLSs, spatially concentrated in the mTLS-core and adjacent to B-cell-rich areas; mIHC further confirmed dense CCL21+ACTA2+ CAFs near CD20+ aggregates. Along an inferred iTLS-to-mTLS continuum, the abundance of CCL21+ CAFs increased, and the expression of chemokines increased. Spatial and transcriptomic analyses further linked B-cell chemotaxis- and activation-related signatures to the CCL21-CCR7 axis, accompanied by germinal centre-like B-cell features. Clinically, higher CCL21 expression, elevated CCL21+ CAF signature scores, and stronger CCL21-CCR7 signatures in B cells were associated with favourable outcomes. Together, these data suggest that CCL21+ CAFs or CCL21 are potential prognostic biomarkers for risk stratification and immune microenvironment profiling and highlight the CCL21-CCR7 axis as a candidate pathway for therapeutic modulation of TLS maturity in PSCC.

Open article ↗



antibodies
2026-09-22 | Reduced Nectin-4 expression in lymph node metastases of penile squamous cell carcinoma: a paired primary–metastatic analysis

Objective To evaluate Nectin-4 expression in primary and matched metastatic penile squamous cell carcinoma (PSCC) lesions and to assess its associations with clinicopathological features and survival outcomes. Methods We analyzed 123 patients with pathologically confirmed PSCC treated at our hospital between 2018 and 2024. Nectin-4 expression was assessed by immunohistochemistry using the H-score (0-300) in primary tumors and 30 matched lymph node metastases, and associations with pathological features, paired primary-metastatic differences, and survival outcomes were analyzed. Results Nectin-4 was widely expressed in PSCC. Higher Nectin-4 expression was observed in less aggressive tumors. Expression was higher in T1 than in T2 stage (95% CI 19.10-79.28; P < 0.01) and decreased from G1 to G3, with significant differences between G1 and G2 (95% CI 0.39-63.83; P = 0.047) and between G1 and G3 (95% CI 24.41-170.43; P = 0.009). Expression in primary tumors was not significantly associated with nodal status. In paired samples, lymph node metastases showed lower H-scores than their matched primary tumors (95% CI 3.52-72.82; P = 0.032). Low Nectin-4 expression was associated with shorter overall survival in Kaplan-Meier and univariable Cox analyses, but it was not independently associated with survival after multivariable adjustment. Conclusions Nectin-4 expression in PSCC is higher in early, better-differentiated tumors and lower in lymph node metastases. Low Nectin-4 expression was associated with poorer overall survival, although it was not an independent prognostic factor. These findings suggest that Nectin-4 may have prognostic relevance and potential value as a therapeutic target in PSCC.

Open article ↗



2026-09-20 | Current Management and Investigational Therapeutic Strategies in Penile Squamous Cell Carcinoma: A Narrative Review.

Penile squamous cell carcinoma (PSCC) is a rare and aggressive genitourinary malignancy requiring integrated multidisciplinary management. This narrative review provides an updated overview of the diagnostic and therapeutic pathway of PSCC from localized disease, where surgery remains the cornerstone of treatment, to locally advanced disease, where multimodal strategies integrating chemotherapy and radiotherapy with surgery are required, and finally to metastatic disease, where systemic therapy becomes the mainstay of treatment. Platinum-based chemotherapy remains the established systemic backbone for advanced PSCC, whereas immune checkpoint inhibitors, chemo-immunotherapy combinations, targeted therapies, antibody-drug conjugates, vaccines, and adoptive cellular therapies represent investigational strategies supported by preliminary evidence. Although these approaches have shown early signals of activity, their routine integration into clinical practice remains limited by small and heterogeneous studies, the lack of definitive randomized evidence, and the need for prospective validation in well-defined clinical and molecular subgroups. The aim of this review is therefore to provide a stage-adapted and multidisciplinary overview of therapeutic strategies for the contemporary management of PSCC.

Open article ↗



2026-09-18 | MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis.

Emerging evidence suggests that combinations of antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) may be effective for advanced penile squamous cell carcinoma (PSCC). These findings support the translation of this strategy into the neoadjuvant setting, offering a novel approach for patients with locally advanced or regionally metastatic disease who have limited treatment options. This single-center, prospective, single-arm, phase II trial evaluates the efficacy and safety of neoadjuvant Becotatug Vedotin plus Pucotenlimab in EGFR-expressing PSCC patients with challenging penile preservation or regional lymph node metastasis. Utilizing a Simon's two-stage design, the primary endpoint is the investigator-assessed R0 resection rate. Secondary endpoints include the downstaging rate, objective response rate (ORR), pathological complete response (pCR) rate, major pathological response (MPR) rate, tumor regression grade (TRG), event-free survival (EFS), disease-free survival (DFS), and organ‑sparing rate. The study plans to enroll 60 patients with EGFR-expressing PSCC. Clinical trial registration: www.clinicaltrials.gov identifier is NCT07518979.

Open article ↗



2026-09-17 | Pre-existing immunity and hrHPV status determine immunotherapy response in advanced penile cancer: biomarkers and overall survival in the PERICLES trial.

Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis. Patients were treated with atezolizumab monotherapy (n=12) or atezolizumab in combination with radiotherapy (n=20, 33 fractions of 1.5-1.8 Gy) for locoregional disease control. Comprehensive analysis of baseline tumor tissue (n=28/31) was performed using bulk RNA sequencing, immunohistochemistry and multiplex immunofluorescence. Additionally, spatial transcriptomics (n=9) was conducted to further explore functionality and (co-)localization of immune cell subsets. With extended follow-up (median: 38 months), landmark 2-year OS and PFS in the full study cohort was 18.8% (95% CI, 9.1-38.6) and 12.5% (95% CI, 5.0-31.3), respectively. High-risk human papillomavirus (hrHPV)-positive tumors were enriched for IFN-γ and IFN-α signatures, potentially explaining the improved PFS and OS observed in this subgroup. Both stromal CD68+ myeloid cell density and intratumoral CD8+PD1+ T-cell density were associated with non-progression at 1 year. Increased intratumoral CD8+PD1+ T-cell density was also associated with improved PFS and OS, with consistent findings in the hrHPV-positive subgroup. Spatial transcriptomics identified these CD8+ T cells as tissue-resident cytotoxic effector cells co-expressing checkpoint molecules (LAG3 and TIGIT), chemokines (CCL4 and CXCL13), and cytotoxic molecules (PRF1 and GZMB). Interrogation of the penile cancer immune microenvironment highlights CD8+PD1+ T-cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.

Open article ↗



2026-08-25 | Multifocal HPV16-positive squamous cell carcinomas in CTLA-4 haploinsufficiency: expanding the spectrum of virus-associated malignancies.

Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) haploinsufficiency is an inborn error of immunity characterized by immune dysregulation, autoimmunity, lymphoproliferation, and an increased risk of malignancy. While susceptibility to oncogenic viral infections has been proposed, the relationship between CTLA-4 haploinsufficiency and human papillomavirus (HPV)-driven carcinogenesis remains poorly characterized. We describe a patient with CTLA-4 haploinsufficiency who developed multiple HPV-associated malignancies. Clinical, pathological, virological, and genetic data were reviewed. Germline genetic testing was performed using whole-exome sequencing, and HPV DNA analysis was conducted on available tumor specimens. A man with a history of alopecia totalis and autoimmune thyroiditis developed five distinct malignancies by the age of 50 years, including Epstein-Barr virus (EBV)-associated gastric Hodgkin lymphoma, cutaneous squamous cell carcinoma (SCC), and three independent HPV16-positive SCCs involving the oral cavity, anus, and penis. Germline testing identified CTLA-4 haploinsufficiency caused by a likely pathogenic CTLA4 variant, c.406C > T (p.Pro136Ser). No additional germline variants associated with hereditary cancer predisposition were detected. HPV DNA analysis demonstrated HPV16 positivity in all three mucosal SCCs. This case expands the spectrum of malignancies associated with CTLA-4 haploinsufficiency and suggests that persistent high-risk HPV infection may represent an underrecognized complication of this disorder. The occurrence of three independent HPV16-positive SCCs raises the possibility that CTLA-4 deficiency predisposes to HPV-driven carcinogenesis and supports further investigation of HPV surveillance and cancer prevention strategies in affected individuals.

Open article ↗



other
2026-07-27 | Vaccine Therapy for the Management of Penile Cancer: Evidence, Opportunities and Challenges.

Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited therapeutic options in advanced and recurrent diseases. Advanced PSCC is typically managed with multimodal therapy, including neoadjuvant chemotherapy or chemoradiation followed by surgery; however, durable responses remain uncommon, and outcomes after recurrence are poor. Cancer vaccines represent a promising immunotherapeutic strategy, as these treatments induce tumor-specific immunity and heightened immune surveillance against penile cancer cells. While therapeutic cancer vaccines have not yet demonstrated consistent clinical efficacy as monotherapy in PSCC, their integration with complementary immune-modulating approaches, particularly immune checkpoint blockade, represents a rational strategy to enhance antitumor immunity. This review summarizes the rationale for vaccine development in PSCC, with emphasis on HPV-derived antigens, neoantigens, and emerging tumor-associated targets. We examine major vaccine platforms, including viral-vector, peptide-based, nucleic acid, and dendritic cell-based approaches. We also discuss how spatial transcriptomics, single-cell RNA sequencing, artificial intelligence-assisted antigen prediction, and nanotechnology-enhanced delivery systems may support future personalized vaccine development. Overall, therapeutic vaccines remain investigational in PSCC but may become relevant within biomarker-driven, combination-based immunotherapy strategies.

Open article ↗



2025-12-18 | Prevalence and time trends of human papillomavirus in penile cancer over 26 years-A comprehensive study of 1040 penile cancer cases from Denmark.

Penile cancer is rare. It has been suggested that approximately half are human papillomavirus (HPV) associated, but large-scale studies on HPV prevalence and time trends are limited. We aimed to examine the high-risk HPV (hrHPV) prevalence in a large single-country study of penile squamous cell carcinomas (SCC) during a 26-year period. From the nationwide Danish Pathology Register, we identified all penile SCCs diagnosed during the period 1995-2020 at hospitals covering most regions in Denmark. Histologic slides were evaluated by expert pathologists, and archived tumor tissue was tested for the presence of HPV DNA using the INNO-LiPA assay. We assessed the overall and type-specific HPV prevalence according to calendar period, age, and histology, and estimated the annual percentage change (EAPC) of hrHPV positivity over the entire study period. We included 1040 penile SCCs. The overall HPV prevalence was 54.5% and the hrHPV prevalence was 50.4%. We observed no change in the prevalence of hrHPV over time (EAPC = -0.03% [95% confidence interval: -0.91; 0.85]). HPV16 was the most prevalent genotype (41.1%), and 50.0% of the penile SCCs had an HPV type that would be covered by the nine-valent HPV vaccine (HPV6/11/16/18/31/33/45/52/58). Penile SCCs with HPV-associated histological features had the highest hrHPV prevalence, particularly tumors exhibiting basaloid features (81.8%-87.7%). In this large population-based study, covering most regions in Denmark, we found no substantial change in hrHPV prevalence during 1995-2020. Our findings suggest that prophylactic vaccination with the nine-valent HPV vaccine could prevent a considerable part of penile SCCs in Denmark.

Open article ↗



2025-09-27 | Evaluating the Evolving Treatment Landscape of Systemic Therapies in Penile Cancer.

Penile squamous cell carcinoma (PSCC) represents a malignancy with low incidence. Despite advances in chemotherapy-based management, outcomes for patients with locally advanced and metastatic disease remain poor, with 5-year survival rates of 51% and 9%, respectively. Early diagnosis is crucial, yet psychosocial/structural barriers often delay it. Treatment strategies are stage-dependent, ranging from organ-sparing surgery and targeted radiotherapy for early-stage disease to cisplatin-based chemotherapy for locally advanced and metastatic cases. However, systemic therapies provide modest survival benefits and can expose the patient to unnecessary toxicities. Immunotherapy has emerged as a promising area, given the high expression of PD-L1 in PSCC and the significant proportion of HPV-driven tumors. Although initial results from immunotherapy-based trials are limited, preliminary trials such as HERCULES, ALPACA, PULSE, and PERICLES aim to define their role better. Similarly, combination regimens utilizing toripalimab in combination with nimotuzumab and taxane-based chemotherapy (TNT) followed by consolidative surgery are currently underway. Furthermore, the development of therapeutic HPV vaccines offers a novel strategy to enhance local antitumor immunity. Antibody-drug conjugates (ADCs) targeting HER-2, Trop-2, and Nectin-4 antigens represent another evolving therapeutic avenue that has shown preliminary promising results. As the landscape of penile cancer treatment continues to grow, incorporating these novel strategies could further improve survival outcomes and/or offer improved quality of life. This review provides a comprehensive overview of emerging systemic therapies in PSCC, underscoring ongoing research efforts to address unmet needs.

Open article ↗



2025-09-05 | Etiologic fraction of HPV-attributed anal and penile squamous cell carcinoma: study in specialized hospitals, Sri Lanka

Introduction The Human Papilloma Virus (HPV) infection is known to cause anogenital cancers. Male HPV prevalence and population-attributable risk (PAR)are important to plan future HPV preventive strategies for HPV-driven anogenital cancers in males. Methods A hospital-based case-control study was carried out to determine the etiologic fraction attributed to HPV-driven anal and penile(anogenital) cancers among male patients presenting to tertiary care hospitals in Gampaha district and Apeksha Hospital (cancer specialized), Sri Lanka and to calculate PAR percentage on anogenital SCC among the study population where HPV prevalence was 5.7%. New or already diagnosed patients for anal and penile SCC who reported to selected hospitals from August 2022 to June 2023 were recruited for data and specimen collection. A sample size of 20 cases and 80 controls were selected, with four controls chosen per case from sexually active, clinically normal men aged 20-70 years residing in the Gampaha district. Additional etiological factors that were checked included the presence of sexually transmitted infections, phimosis, anogenital injury, and the use of tobacco, alcohol or illegal drugs. The chi-square test was used at the level p<0.05 significance. Bivariable and logistic regression analyses were used to calculate odds ratios (ORs). Results A significantly associated factor for getting anal and penile SCC was HPV infection (p<0.001; adjusted OR: 27.7; 95% CI: 4.3,177.8).For any HPV genotype & high-risk HPV genotype, prevalence was 55% & 50% among cases and 5% & 2.5% among controls respectively. Assuming prevalence among controls as the population prevalence, the calculated PAR% was 62.2% for any HPV genotype and 33% for the HPV 16 HR genotype. Conclusions Sixty-two per cent of the anal and penile SCCs were attributed to any HPV genotype and one-third of anal and penile SCCs can be prevented by introducing HPV 16 genotype-containing vaccine to male.

Open article ↗



2025-05-28 | Effect of exosome-derived lncRNA on MAL + CTL apoptosis in remodeling of the immune microenvironment in HPV + penile squamous cell carcinoma.

e17022 Background: Patients with HPV + PSCC have a poor prognosis, and the immune escape mechanisms remain a major challenge in improving clinical outcomes. This study aims to investigate the role of exosome-derived long non-coding RNAs (lncRNAs) in modulating the immune microenvironment, particularly through their interaction with MAL + CTLs in HPV + PSCC. Methods: We collected tumor samples from HPV + PSCC patients and performed scRNA-seq to analyze the distribution and functional state of immune cells within the tumor microenvironment. Spatial transcriptomics were employed to explore the spatial localization of Tregs and CTLs within the tumor. Exosomes were isolated from the culture media of Treg cells and analyzed for the presence of lncRNAs. Additionally, the interaction between exosome-derived lncRNAs and miRNAs, particularly hsa-miR-619-3p, was examined in vitro. The impact of exosome-derived lncRNAs on MAL + CTL apoptosis was assessed using flow cytometry and apoptosis assays. Results: Our clinical data and scRNA-seq analysis revealed that HPV + PSCC tumors are characterized by an increased proportion of Treg cells and a decreased presence of CD8 + CTLs compared to HPV- PSCC or normal tissues. Importantly, we observed a significant correlation between the number of Tregs and the severity of immune suppression in HPV + PSCC. Spatial transcriptomics further revealed that Tregs were predominantly located in close proximity to CD8 + CTLs within the tumor microenvironment, suggesting potential interactions between these cell populations. Interestingly, exosome isolation from Tregs confirmed the presence of exosome-derived lncRNAs, which were shown to significantly alter the miRNA profile in surrounding immune cells. Specifically, we identified that exosome-derived lncRNAs from Tregs bound to hsa-miR-619-3p, a miRNA previously linked to T-cell dysfunction and immune evasion. We further demonstrated that this interaction led to an increase in MAL expression in CTLs, which in turn triggered their apoptosis. Flow cytometry analysis revealed that exposure to exosome-derived lncRNAs from Tregs resulted in a significant increase in MAL + CTLs and a concomitant increase in CTL apoptosis. Besides, the in vivo experiments using HPV + PSCC xenografts in mice showed that Treg-derived exosomes significantly impaired anti-tumor immunity, leading to increased tumor growth and reduced CTL infiltration in the tumor. Importantly, inhibition of MAL expression in CTLs by RNA interference rescued CTL function and partially restored anti-tumor immunity, confirming the pivotal role of MAL + CTLs in immune suppression. Conclusions: Our findings reveal a novel mechanism of immune evasion in HPV + PSCC, where Tregs secrete exosome-derived lncRNAs that interact with miR-619-3p to upregulate MAL expression in CTLs, leading to their apoptosis.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.